Coherus Oncology can sell up to $50,000,000 of common stock through Leerink Partners under an at-the-market arrangement. Investors should weigh the potential funding against the stated risk of immediate, potentially substantial dilution, while management retains broad discretion over general corporate use of any net proceeds.

Key Highlights

  • The sales agreement with Leerink Partners is dated August 28, 2026.
  • Coherus Oncology’s shelf prospectus permits securities offerings up to $150.0 million.
  • The company’s common stock had a last reported sale price of $1.46 per share on August 27, 2026.

Coherus Oncology, Inc. (NASDAQ: CHRS) may sell up to $50,000,000 of common stock through Leerink Partners under an at-the-market arrangement. Net proceeds, if any, are intended for general corporate purposes, while the number of shares sold and the amount raised will depend on market prices and sales volume.

$50,000,000 Offering Sets Sales Framework

The sales agreement dated August 28, 2026, covers Coherus common stock with a $0.0001 par value.

Leerink Partners may act as sales agent or principal, with transactions conducted at market prices through the Nasdaq Global Market or another agreed method. Coherus may prevent sales below a designated price, and either party may suspend or terminate the arrangement with written notice.

Proceeds Use and Dilution Risk

Management will have broad discretion over the money’s application. The risk disclosures warn that buyers may face immediate dilution if the offering price exceeds net tangible Book Value per share, and that such dilution may be substantial.

Peers Moving on This News